Relaxin-based modulation of pain
Project leader : Pascal Darbon
This is a collaborative project together with Prof. Marc Landry, Bordeaux, France, Prof. Andrew Gündlach, Melbourne, Australia, and Dr. Ipek Yalcin
, Strasbourg. More than 60% of chronic pain patients suffer pathological anxiety, thus making pain comorbidities a major public health issue. However, these conditions are poorly managed clinically, despite their prevalence and broad impact. Investigations of pain and anxiety are mostly conducted separately, but more knowledge of the interactions between affective and pain circuits is the key to developing better treatment strategies. In the course of this project, we will explore the capacity of a highly-conserved peptidergic system to alleviate both pain and anxiety. Indeed, considerable evidence support a role for neuropeptides in the control of anxiety and pain. Therefore, the objectives of this novel, collaborative project are to: (i) determine the role of relaxin-3/RXFP3 signalling in the plasticity of circuits associated with pain and comorbid anxiety, and (ii) develop a novel strategy to treat pathological pain and comorbid disorders by targeting a widespread peptidergic signalling network.
Prof. Marc Landry, Bordeaux, France; Prof Andrew Gundlach, Melbourne, Australia.
Prof. Andrew Gundlach group peptide neurobiology, Florey Institute of Neuroscience and Mental Health, Australia.
Prof. Landry group purinergic-mediated neuroinflammation and brain disorders, UMR5293, Bordeaux, France.
Dr. Yalcin group neuroanatomy, pain and psychopathology, UPR3212, Strasbourg, France.